Quarterly Financial Results
Beta Drugs Q1 FY27 Results: Revenue Rises 25% YoY to ₹125.5 Crore, PAT Grows 41% QoQ
NSE
beta
BSE
not listed
- Beta Drugs Limited reported a strong start to FY27 with consolidated revenue increasing to ₹125.5 crore, while EBITDA margin improved to 21.83% and PAT margin expanded to 13.15%.
- The company also strengthened its growth platform through the consolidation of Nivian Lifesciences’ IVF business and continued expansion across oncology, exports and contract manufacturing.
PRICE-SENSITIVE TRIGGER
Event: Q1 FY27 Investor Presentation and Financial Performance Update
Type: Quarterly Financial Results
Impact: Positive
Immediate Effect: The company delivered healthy revenue growth along with sequential improvement in profitability and operating margins, supported by diversified business segments and continued expansion into specialty therapies.
Metrics:
Key Financial Metrics:
- Revenue from Operations: ₹125.5 crore (+25.2% YoY, +33.5% QoQ)
- EBITDA: ₹27.4 crore (+39.1% YoY, +54.8% QoQ)
- EBITDA Margin: 21.83% (vs 19.66% in Q1 FY26)
- PAT: ₹16.5 crore (+41.0% YoY, +83.3% QoQ)
- PAT Margin: 13.15% (vs 11.68% in Q1 FY26)
- 5-Year Revenue CAGR: 27%
- 5-Year EBITDA CAGR: 25%
- 5-Year PAT CAGR: 29%
- ROCE (FY26): 31%
- Debt-to-Equity (FY26): 0.60x
Highlight:
- Beta Drugs reported its highest quarterly revenue of ₹125.5 crore, while EBITDA margin expanded to 21.83% and PAT margin improved to 13.15%, reflecting improved operating efficiency.
What Happened ?
Beta Drugs reported strong quarterly growth across revenue and profitability as its diversified oncology-focused business continued to scale. During the quarter, the company benefited from contributions across branded formulations, contract manufacturing (CMO), exports and APIs.
The company also consolidated the IVF business of Nivian Lifesciences Pvt. Ltd., following the acquisition of a 66.09% stake in April 2026. This marks Beta Drugs’ entry into the fast-growing assisted reproductive care market, adding a new specialty growth vertical beyond oncology.
key details
Business & Operational Highlights:
- Consolidated Nivian Lifesciences’ IVF business into domestic branded formulations from FY27.
- Oncology business continues to reach 85%+ of India’s corporate and government hospitals.
- Operates through four diversified revenue pillars:
- Domestic Branded Formulations
- Contract Manufacturing (CMO)
- Exports
- APIs
- Presence across 26+ countries with over 280 dossier registrations globally.
- Operates three WHO-GMP certified manufacturing facilities, including international regulatory approvals such as ANVISA, INVIMA and COFEPRIS.
- Oncology portfolio comprises 180+ SKUs, with 8 products currently under development.
- R&D pipeline includes 13 products developed during FY25–FY26 and 24 planned launches during FY27–FY29.
- API business continues strengthening backward integration, with nearly 70% of APIs used internally for formulations manufacturing.
Note:
- The addition of IVF alongside oncology, dermatology, APIs and CMO broadens Beta Drugs’ specialty pharmaceutical platform while reducing dependence on a single therapeutic segment.
Risk Analysis
Summary:
- Despite strong quarterly performance, the business remains exposed to regulatory approvals, product commercialization timelines and execution of expansion initiatives across multiple specialty segments.
Key Risks:
- Oncology continues to contribute a significant portion of overall business.
- International expansion depends on timely product registrations and regulatory approvals.
- Continued investment is required to commercialize products under development.
- Growth from the IVF business depends on successful integration of Nivian Lifesciences.
- Pharmaceutical pricing and competitive pressures may affect future margins.
Worst Case:
- Delays in product approvals, slower export registrations or weaker-than-expected integration of the IVF business could moderate future revenue growth and margin expansion.
Risk Level: Medium
Company Commentary
Management highlighted the following strategic priorities:
- Continue strengthening leadership in specialty oncology therapies.
- Expand the IVF business following the acquisition of Nivian Lifesciences.
- Increase contribution from exports and international registrations.
- Enhance profitability through high-margin CMO products and novel drug delivery technologies.
- Continue investing in product development, R&D and manufacturing capabilities to support long-term growth.
Official Exchange Filing: Beta Drugs Limited
